Revolo Biotherapeutics Announces Presentations at Upcoming Medical Meetings
May 10, 2023 08:00 ET
|
Revolo Biotherapeutics
NEW ORLEANS and CAMBRIDGE, United Kingdom, May 10, 2023 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that reset the immune system to achieve...
Revolo Biotherapeutics Announces Positive Topline Data from Phase 2a Trial of ‘1104 in Adults with Active Eosinophilic Esophagitis
April 19, 2023 08:00 ET
|
Revolo Biotherapeutics
- Data shows achievement of primary endpoint of decreasing esophageal intraepithelial eosinophil count and positive impact on an array of histological measures of EoE – - Favorable safety and...
Revolo Biotherapeutics to Present at the 8th Food Allergy Fund Summit
April 13, 2023 08:00 ET
|
Revolo Biotherapeutics
NEW ORLEANS and CAMBRIDGE, England, April 13, 2023 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo Bio” or the “Company”), a company developing therapies that reset the immune system to achieve...
Revolo Biotherapeutics Announces Completion of Phase 2a Trial of ‘1104 in Allergic Disease
March 27, 2023 08:00 ET
|
Revolo Biotherapeutics
NEW ORLEANS and CAMBRIDGE, England, March 27, 2023 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo Bio” or the “Company”), a company developing therapies that reset the immune system to achieve...
Revolo Biotherapeutics Presents New Data Demonstrating Long-Lasting Effect of ‘1104 in a Food Allergy Model at the 2023 AAAAI Annual Meeting
February 28, 2023 08:00 ET
|
Revolo Biotherapeutics
NEW ORLEANS and CAMBRIDGE, United Kingdom, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo Bio” or the “Company”), a company developing therapies that reset the immune system to...
Revolo Biotherapeutics to Present Recently Generated Data at the 2023 AAAAI Annual Meeting Demonstrating Anti-inflammatory Effect of ‘1104 in Food Allergy
February 06, 2023 08:00 ET
|
Revolo Biotherapeutics
NEW ORLEANS and LONDON, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that reset the immune system to achieve superior...
Revolo Biotherapeutics Completes Enrollment in Phase 2 Trial of ‘1104 in Allergic Disease
January 05, 2023 08:00 ET
|
Revolo Biotherapeutics
NEW ORLEANS and LONDON, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that reset the immune system to achieve superior long-term...
Revolo Biotherapeutics to Present at TIDES Europe 2022
November 14, 2022 08:00 ET
|
Revolo Biotherapeutics
NEW ORLEANS and LONDON, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that reset the immune system to achieve superior...
Revolo Biotherapeutics Announces That the Last Patient in its Phase 2a Trial of ‘1104 in Eosinophilic Esophagitis has Completed the Study
November 09, 2022 08:00 ET
|
Revolo Biotherapeutics
NEW ORLEANS and LONDON, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that reset the immune system to achieve superior...
Revolo Biotherapeutics Awarded Patent for ‘1104 in Acute Treatment of Relapsing Remitting Conditions
November 02, 2022 08:00 ET
|
Revolo Biotherapeutics
NEW ORLEANS and LONDON, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that reset the immune system to achieve superior...